Niopam 200, Solution for Injection, glass bottles

Land: Írland

Tungumál: enska

Heimild: HPRA (Health Products Regulatory Authority)

Virkt innihaldsefni:

Iopamidol

Fáanlegur frá:

Bracco Imaging spa

ATC númer:

V08AB; V08AB04

INN (Alþjóðlegt nafn):

Iopamidol

Skammtar:

200 milligram(s)

Lyfjaform:

Solution for injection

Gerð lyfseðils:

Product subject to prescription which may not be renewed (A)

Lækningarsvæði:

Watersoluble, nephrotropic, low osmolar X-ray contrast media; iopamidol

Leyfisstaða:

Not marketed

Leyfisdagur:

1983-03-10

Upplýsingar fylgiseðill

PACKAGE LEAFLET: INFORMATION FOR THE USER
NIOPAM 200 SOLUTION FOR INJECTION
(Iopamidol)
The name of your medicine is Niopam 200 solution for injection, which
will be called Niopam
throughout this leaflet.
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you. Do not pass it on to
others.
It may harm them, even if their symptoms are the same as yours.
- If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet, see section 4. WHAT IS IN THIS LEAFLET
:
1. What Niopam is and what it is used for
2. What you need to know before you are given Niopam
3. How you are given Niopam
4. Possible side effects
5. How to store Niopam
6. Contents of the pack and other information
1. WHAT IS NIOPAM AND WHAT IT IS USED FOR
Niopam is a special dye (or contrast agent) which blocks X-rays
because it contains iodine. Niopam
works by helping your doctor to see the internal body structures on an
X-ray picture. Your doctor
has prescribed Niopam to help view the blood vessels, spine or brain
using X-rays.
This medicine is for diagnostic use only.
2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN NIOPAM
YOU SHOULD NOT BE GIVEN NIOPAM IF YOU:
• Are allergic to Iopamidol, any other ingredients of this medicine
(listed in Section 6)
• Are currently receiving corticosteroids injection into your spine
TAKE SPECIAL CARE WITH NIOPAM AND TELL YOUR DOCTOR IF YOU HAVE ANY OF
THE FOLLOWING
CONDITIONS:
• A history of allergy or asthma
• Diabetes
• Heart problems
• High blood pressure in the lungs
• Kidney or liver problems
• Over-active thyroid gland (this is particularly important in
newborn babies)
• A history of epilepsy
• Myelomatosis (Cancer of the plasma cells in the blood)
• Severe systemic disease (a disease affecting more tha

Vara einkenni

Health Products Regulatory Authority
10 June 2021
CRN00CF05
Page 1 of 11
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Niopam 200, Solution for Injection, glass bottles
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
The solution contains 40.82% w/v Iopamidol equivalent to 200mg
iodine/ml.
Each ml contains 408.2 mg of Iopamidol.
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Solution for Injection.
A clear aqueous solution.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
This medicinal product is for diagnostic use only.
X‑ray contrast medium for use in lumbar and thoraco-cervical
myelography, and in computer tomography enhancement.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Method of administration
Intrathecal
Intravenous.
Posology
NIOPAM 200: DOSAGE SCHEDULE
Procedure
Dosage
Lumbar
Adults 10 - 50 ml
Thoraco-Cervical
Adults 5 - 15 ml
Computer Tomography
Adults Brain scanning 50 - 100ml
Whole body scanning 40-100ml
Health Products Regulatory Authority
10 June 2021
CRN00CF05
Page 2 of 11
The dosage must be adapted to the examination, the age, body weight,
cardiac output, renal function, general condition of the
patient and the technique used. Usually the same iodine concentration
and volume are used with other iodinated x-ray
contrast in current use.
As with all contrast media, the lowest dose necessary to obtain
adequate visualisation should be used.
Non‑ionic contrast media have less anti‑coagulant activity
_in‑vitro_ than ionic media. Meticulous attention should therefore
be paid to angiographic technique. Non‑ionic media should not be
allowed to remain in contact with blood in the syringe and
intravascular catheters should be flushed frequently, to minimise the
risk of clotting, which rarely has led to serious
thromboembolic complications after procedures.
Therefore, meticulous angiographic techniques are recommended
including close attention to guide wire and catheter
manipulation, use of manifold systems and/or three-way stopcocks,
frequent catheter flushi